

# Pixium Vision / Second Sight Medical Products Business Combination

January 6<sup>th</sup> 2021



# Legal Disclaimer



## Additional Information and Where to Find It

In connection with the proposed transaction between Second Sight Medical Products, Inc. ("Second Sight") and Pixium Vision, Second Sight will file with the United States Securities and Exchange Commission (the "SEC") preliminary and definitive proxy statements and will mail a definitive proxy statement to its shareholders as of the record date established for voting on the proposed business combination. **SECOND SIGHT'S SHAREHOLDERS AND OTHER INTERESTED PERSONS ARE ADVISED TO READ, ONCE AVAILABLE, THE PRELIMINARY PROXY STATEMENT AND ANY AMENDMENTS THERETO AND, ONCE AVAILABLE, THE DEFINITIVE PROXY STATEMENT, IN CONNECTION WITH SECOND SIGHT'S SOLICITATION OF PROXIES FOR ITS SPECIAL MEETING OF STOCKHOLDERS TO BE HELD TO APPROVE, AMONG OTHER THINGS, THE PROPOSED BUSINESS COMBINATION, BECAUSE THESE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION ABOUT SECOND SIGHT, PIXIUM VISION AND THE PROPOSED BUSINESS COMBINATION.** Second Sight's shareholders may also obtain a copy of the preliminary or definitive proxy statement, once available, as well as other documents filed with the SEC by Second Sight, without charge, at the SEC's website located at [www.sec.gov](http://www.sec.gov) or by directing a request to: Second Sight Medical Products, Inc., 12744 San Fernando Road, Suite 400, Sylmar CA 91342. The information contained on, or that may be accessed through, the websites referenced in this presentation is not incorporated by reference into, and is not a part of, this press release.

## FORWARD LOOKING STATEMENTS

This document contains information which includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The actual business results may differ from expectations, estimates and projections and consequently, readers should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "propose," "plan," "contemplate," "may," "will," "shall," "would," "could," "should," "believes," "predicts," "potential," "continue," "positioned," "goal," "conditional" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the intention to pursue the business combination and to announce information regarding the business combination, as well as statements regarding the combined company's markets and competitive position, and more specifically, on the size of its potential markets. This information has been drawn from various sources or from the companies' own estimates. Investors should not base their investment decision on this information. These statements are not a guarantee of the combined company's future performance. These forward-looking statements relate to the combined company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Since forward-looking statements cannot under any circumstance be construed as a guarantee of the combined company's future performance and that the combined company's actual financial position, results and cash flow, as well as the trends in the sector in which the combined company operates may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Furthermore, even if the combined company's financial position, results, cash-flows and developments in the sector in which the combined company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the combined company's future results or developments. Neither Second Sight nor Pixium undertakes any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this presentation. A description of those events that may have a material adverse effect on the business, financial position or results of the combined company, or on its ability to meet its targets, appears in (i) the sections "Risk Factors" of Pixium Vision's "Document de Base" filed with the French Autorité des Marchés Financiers and (ii) risks and uncertainties described in or implied by the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of Second Sight's Annual Report on Form 10-K, filed on March 19, 2020, Form 10K/A filed April 28, 2020, and Forms 10-Q filed June 26, 2020, August 13, 2020, and November 12, 2020, and other reports filed by Second Sight from time to time with the SEC. By attending this presentation or accepting this document, you agree to be bound by the foregoing restrictions set out above.

# Experienced Management Team



**Lloyd Diamond, CEO**

- 25+ years experience in the MedTech industry
- Extensive experience in development, commercial and financing in orthopedic, ophthalmology and other clinical segments



**Guillaume Renondin, CFO**

- 30+ years finance experience – Aeronautic, Automotive and Startups
- Senior Advisor Grant Thornton Executive



**Guillaume Buc, CTO**

- 20+ years MedTech industry experience
- GE Healthcare (1995-2013) – CTO Interventional Cardiology R&D



**Ralf Hornig, Clinical Affairs Dir.**

- 20+ years retinal implant technology experience
- Since 2001, working with IMI then Pixium



**Karine Chevrie, RA/QA Dir.**

- 20+ years MedTech industry experience
- EOS Imaging (2006-2015) – QA/Reg Director



**Lisa Olmos de Koo, Chief Med. Adv.**

- 15+ years medical experience
- Retina surgeon and Associate Professor – University of Washington School of Medicine

# Developments Supported and Advised by Knowledgeable Scientific and Medical Experts



Prof. José-Alain  
Sahel

*Vision Institute  
(France) and  
UPMC (Pittsburgh  
(USA)*



Prof. Frank G.  
Holz

*University  
Hospital Bonn  
(Germany)*



Prof. Daniel  
Palanker

*Stanford  
University  
(USA)*



Dr. Yannick  
Le Mer

*Fondation  
Adolphe de  
Rothschild  
(France)*



Prof. Borja  
Corcostegui

*IMO, Institute of  
Ocular  
Microsurgery  
(Spain)*



Dr. Mahi  
Muqit

*Moorfields Eye  
Hospital  
(UK)*



Prof. Andrea  
Cusumano

*University of  
Rome (Italy)*



Prof. Jan Van  
Meurs

*Rotterdam Eye  
Hospital  
(Netherlands)*

- International
- Multidisciplinary: from basic science to medical expertise
- Highly recognized and respected


# Contemplated Combination



- Pixium aims to create a world of bionic vision for those who have lost their sight, enabling them to regain partial visual perception and greater autonomy



- Second Sight Medical Products develops, manufactures, and markets implantable visual prosthetics to provide artificial vision to blind individuals seeking greater independence



- Combined entity will continue to trade on the Nasdaq
- Financing use of proceeds will fund the combined group ongoing business

# Combination Offers Synergies



One product company with limited organizational synergies



Aiming to treat Dry Age Related Macula Degeneration (AMD)



Expertise in implants and image capture and processing



Strong IP position with limited resources

One product company with limited organizational synergies

Aiming to treat glaucoma, diabetic retinopathy, optic nerve disease, and eye trauma

Expertise in artificial intelligence and Virtual/Augmented reality

Strong IP position with limited resources


Becoming a global leader, multiple product ophthalmology company with strong organizational synergies

Combined entity has potential to treat nearly all forms of blindness



Leveraging technologies across platforms to create best image processing combined with VR/AR allow to sell additional “services”

Combined IP position eliminates challenges between each other and raises barrier to entry

# Structure and Timing of the Business Combination



**Business Combination Expected to Close late Q1/early Q2 2021**



# Pixium Vision



SECOND SIGHT



# Pixium Vision Company Overview: Investing Into the Last Stage of Clinical Development



## Focus: Neuromodulation in ophthalmology

- Brain-machine technology company leveraging proprietary algorithms and artificial intelligence to develop bionic vision system for the treatment of retinal dystrophies
- Developing the Prima Retinal Implant System
  - Helps visually impaired patients regain sight through neuromodulation
- Only ophthalmology treatment modality with the potential to restore vision rather than halt or manage vision decline

## Progress: Entering the Final Development Stage

*So far, 7 patients have received treatment with the Prima system*

- The Prima System exceeded its primary endpoint:
  - Demonstrated successful letter reading in the central retinal area
- Proof of Concept validated in dry-AMD – a disease with no current therapeutic solution
- We believe the Prima system can become 1<sup>st</sup> therapeutic solution in Dry-AMD
  - A \$1.25B initial market opportunity

## Next Development Steps

- PRIMAVERA pivotal study in dry-AMD has been filed, read-out late 2022
- PRIMA U.S. Early Feasibility Study (EFS) initiated in Q1 2020: two patients successfully implanted

# Shifting from an R&D Focused Company to a Commercially Focused Company



**2011 – 2019**

- First generation retinal implant for Retinitis Pigmentosa released to market
- Validated through several iterations of implants and image processing systems
- Sub-retinal implant manufacturing process to meet commercial demand
- Generated data in five patients

2019



**2019 – 2023**

- New CEO hired with proven MedTech product development and launch experience
- De-risked PRIMAVERA pivotal study to improve chance of success
- Clear objective to generate data in larger patient population in the U.S. and EU
- Laser focused on getting Prima System CE marked in 2022/23 and FDA approved

**Foundations Set in Place**


**Pixium Vision Enters its Next Phase**

# Addressing a Large Unmet Need in Dry-AMD, Which Affects 80-90% of AMD Patients

*The Well Served Wet-AMD Market Vs. the Underserved Dry-AMD Market*

## Age-related Macular Degeneration


- Eye disease leading to progressive loss of central vision
- Onset mostly around 60 years old
- Significant impact on quality of life, impeding ability to read, transportation, social interactions, and other daily tasks
  - Loss of quality of life for advanced AMD patients is comparable to dialysis, advanced prostate cancer or severe stroke<sup>1</sup>



(1) Trans Am Ophthalmol Soc. 2005 Dec; 103: 173–186

(2) Based on 2018 Global sales: Lucentis (Roche/Novartis) \$3.7B and Eylea (Bayer/Regeneron) \$6.7B

# Progressive Loss of Visual Acuity in AMD Patients Leads to Dramatic Loss in Quality of Life



**Loss of Quality of Life for advanced AMD patients is comparable to Dialysis, advanced Prostate cancer or severe Stroke**

(1) Trans Am Ophthalmol Soc. 2005 Dec; 103: 173–186

(2) DALY: Disability-Adjusted Life Year: DALYs sum years of life lost (YLL) due to premature mortality and years lived in disability/disease (YLD)

# Prima System Pricing Expected Well Below Commonly Accepted Efficacy Based Pricing



Usually accepted US\$150,000 per QALY



Usually accepted €50,000 per QALY

Prima System Planned US\$75,000 pricing



QALY = 1.5-2.5<sup>(1)</sup>



Pricing per QALY

~US\$20,000-50,000 / QALY


~ €18,000-45,000 / QALY

Pricing per QALY well below commonly accepted price per QALY

(1) Company expectations based on clinical data generated to date


QALY: Quality-Adjusted Life Year: A QALY is the arithmetic product of life expectancy combined with a measure of the quality of life-years remaining

# Initially Targeting 15,000 U.S. & Europe Dry-AMD Patients, with Potential to Address 120,000



(1) Assumes Prima system planned price of US\$75,000

# Focusing on All Treating Referral Centers to Most Efficiently Target Patients in Need



Limited Commercial Infrastructure Needed

# Pixium's Prima System Initial Market Potential




**Prima System could generate over US\$400m in annual revenues based on the following assumptions**


- 20% market penetration in patients with established dry-AMD 7-years post launch
- 30% market penetration in newly diagnosed patients 7-years post launch

## **Key drivers for fast and sustained market uptake**

- Well identified and concentrated patient pool with no therapeutic options currently
- Natural ageing of the population leading to incidence and prevalence growing faster than overall population

**Prima Initial Market Potential in the targeted patient population in US\$m per year**





# Prima System: Breakthrough Machine-brain Interface for Dry-AMD




# Prima System, a Cutting-Edge Technology Supported by Multi-disciplinary Partners

## Universities and Research Institutes





## Vision Clinics



# Prima System

**The Prima System is a miniaturized photovoltaic wireless sub-retinal implant that is implanted underneath the retina in a surgical procedure**

- Partially replaces the normal physiological function of the eye's photoreceptor cells
  
  
  
- The Prima System is composed of three main elements:
  - Wireless retinal implant
  - Pair of glasses with a camera and digital projector
  - Pocket processor
  
  
  
- Electrically stimulates the nerve cells of the inner retina
  - Transmits the visual information to the brain via the optic nerve
  
  
  
- Aims to elicit functional artificial, or bionic, vision in the form of light perception
  - Replaces partially the natural central vision loss




# Prima System – 3 Step Visualization Process



## Step 1

Generating Signal based on surrounding environment




## Step 2

Transmitting Signal to sub-retinal implant



## Step 3

Converting Signal into retina stimulation




- Mini-camera captures images of the environment as a video stream and send it to pocket computer
- Pocket computer transforms the images into stimulation signals using proprietary algorithms and send back signals to glasses



- Glasses project via laser a pattern at the back of the eye based on signal received from image analysis system
- This laser stimulates specific cells of the sub-retinal implant

- Stimulated implant cells use photovoltaic property to transform energy received from laser beam into electric current/stimulation
- Electric current stimulates retina leading to optical nerve stimulation and brain interpretation of stimulus



# An Elegant Solution for Vision Restoration









## Clinical Development



# Clinical Data<sup>1</sup> Show Extreme Improvement at 18 Months



*PRIMA is the only implant that meaningfully restores central vision*



Prima 1 data generated with 1<sup>st</sup> generation Visual Processor



Prima 2 Data in Q1 2020 with 2<sup>nd</sup> generation Visual Processor




(1) France first-in-human study (PRIMA FS) recruited 5 patients. Primary endpoint is Elicitation of visual perception at 18 months with up to 36-month follow-up

## Word reading with second generation glasses






Data obtained from patient training session

# EU & U.S. Clinical Development Overview



- ✓ Scope to obtain both U.S. and EU market approval in close proximity to one another
- ✓ Alternatively U.S. market approval could be pursued later with next generation device that will expand the potential patient pool




## Conclusion



SECOND SIGHT

# Pixium Vision Equity Story

- 
- 1 State of the art ophthalmic neuromodulation platform
  - 2 Expected to be the first approved Dry-AMD solution
  - 3 Promising clinical data shows significant vision improvements in 18 months
  - 4 Accelerated clinical pathway for U.S. and European market approvals
  - 5 Potential to address up to 3.8M Dry-AMD patients in U.S. and Europe
  - 6 Favorable reimbursement landscape suggests ASP of \$75,000 per patient
  - 7 TAM of \$9 Bn expected to facilitate >\$400M peak sales with conservative adoption assumptions
  - 8 Supported by top-tier KOL group



## Second Sight Medical Products



# Orion® Visual Cortical Prosthesis



- Aims to treat glaucoma, diabetic retinopathy, optic nerve disease, and eye trauma
- Six subject feasibility study at UCLA and Baylor has positive results that support advancement
- Leverages Argus® II technology including:
  - Implantable array
  - External and proprietary software/ algorithms for creating artificial vision
- Bypasses retina and optic nerve to stimulate the portion of the brain responsible for vision



# Orion® Interim Study Results Support Advancement to Pivotal

Ongoing six subject Early Feasibility Study at UCLA Medical Center and Baylor

Initial results from first six subjects at 12 months			
Safety	Square Localization (SL)	Direction of Motion (DOM)	FLORA
1 SAE (seizure) 6 AEs (2 subjects, 4* subjects with no AEs)	5 of 6 Perform Better with Orion® System ON versus OFF	6 of 6 Perform Better with Orion® System ON versus OFF	5 of 6 Receive Benefit from Orion® System while Performing Daily Tasks

Observations from rehab session indicate subjects can perform tasks with Orion® that they could not do without


*Examples include:*

- Locate people in front of them
- Walk down sidewalk independently and identify parked cars and driveways
- Identify cue ball and striped calls on a pool table
- Sort light from dark laundry
- Identify and blow out candles on a birthday cake

\*Four subjects not experiencing any device or procedure-related AEs of June, 17 2019 IMSM adjudication meaning

# Orion® Addressable Market and U.S. Reimbursement Strategy

Initial target populations in U.S. represents a \$1 bn plus market opportunity<sup>(1)</sup>



## Several CMS Coverage Pathways for Orion®

**1** Automatic Transitional Coverage to FDA Breakthrough Devices (Proposed Bill)

It is not approved yet. Several new bills on this topic are being proposed

**2** FDA-CMS Parallel Review (Fast Track Pathway)

Currently, it is the fastest pathway to national coverage

**3** National Coverage with Evidence Development




Conditional coverage pathway for products with limited evidence

**4** Local Coverage with Medicare Administrative Contractors

Local coverage through regional Medicare Contractors


(1) Assumes an average selling price of \$250k per device

(2) Based on company estimates and 3<sup>rd</sup> party market research




# Thank you

Lloyd Diamond, CEO | [ldiamond@pixium-vision.com](mailto:ldiamond@pixium-vision.com)



## **Appendix A: Business Combination Rationale**

# Additional Combination Rationale



Fully integrated company

Fully integrated company

Economies of scale  
R&D, G&A, manufacturing

Industrial capabilities  
already validated

Limited manufacturing capabilities

Optimizing manufacturing  
capabilities

Strong EU network of  
ophthalmologists and  
reference centers

Strong U.S. network of  
ophthalmologists and  
reference centers

Strong global network of  
ophthalmologists and  
reference centers

Limited U.S. market access  
capability and starting  
U.S. presence

Already advanced in  
U.S. market access

Strong U.S. and EU presence  
leveraging internal and  
external organizations

# Additional Combination Rationale (Continued)



Limited Market Cap and trading volume EU located

Limited market cap and trading volume despite U.S. located




Larger market cap higher trading volume driving capital flexibility

---

Investors EU focused


Investors U.S. focused

Synergistic investor relations from both geographic and market cap perspectives




## **Appendix B: Additional Prima Information**

# The Role of the Retina and How Eye Disease Leads to Progressive Loss of Central Vision



# Prima System – Machine-Brain Interface Technology Using Artificial Intelligence



# With the Prima System, the Signal to the Brain is Restored

